2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Endocrine
2
Breast
1
Conditions
Breast Neoplasms
275
Carcinoma, Intraductal, Noninfiltrating
25
Breast Carcinoma In Situ
21
Neoplasm Metastasis
14
Neoplasms
13
Breast Neoplasms, Male
12
Ovarian Neoplasms
10
Inflammatory Breast Neoplasms
7
Glioblastoma
6
Endometrial Neoplasms
6
Prostatic Neoplasms
5
Central Nervous System Neoplasms
5
Gliosarcoma
4
Fallopian Tube Neoplasms
4
Breast Cancer Female
4
Brain Neoplasms
4
Recurrence
3
Obesity
3
Hot Flashes
3
Glioma
3
Carcinoma, Ovarian Epithelial
3
Carcinoma, Ductal, Breast
3
Breast Diseases
3
Astrocytoma
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Sleep Wake Disorders
2
Sarcoma
2
Pancreatic Neoplasms
2
Oligodendroglioma
2
Interventions
Fulvestrant
5
Exercise
5
Eating
5
Standard of Care
3
Sodium Chloride
3
Diet
3
Alpelisib
3
ribociclib
2
gallium Ga 68 dotatate
2
exemestane
2
Vitamin D
2
Tamoxifen
2
Magnetic Resonance Spectroscopy
2
Letrozole
2
Ethanol
2
Blood Specimen Collection
2
Anastrozole
2
zopiclone
1
ziprasidone
1
veliparib
1
testosterone undecanoate
1
testosterone enanthate
1
pazopanib
1
mirabegron
1
methyl hydroxyethyl cellulose
1
lenvatinib
1
fluorocholine
1
evolocumab
1
dimethandrolone-undecanoate
1
cyclopropapyrroloindole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Multiple Endocrine Neoplasia Type 1
×
Tamoxifen
×
Clear all
NCT04300790
2025-07-29
METALLICA
MedSIR
Phase 2
Completed
69 enrolled
NCT02753686
2023-02-15
Treat ER+ight
Novartis
Completed
440 enrolled